Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Mayne Pharma Group Limited reported a 5% increase in revenue to $408.1 million and a substantial 105% rise in underlying EBITDA to $47.0 million for the fiscal year ending June 30, 2025. The company’s financial performance was bolstered by improved cash flow from continuing operations, which surged by 460% to $45.4 million. This growth reflects the company’s strategic focus on its women’s health and dermatology businesses, which benefited from effective channel management and targeted initiatives. Despite a net loss after tax of $90.1 million, the results indicate a positive trajectory in operational efficiency and market engagement.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company based in Australia, primarily focused on developing and manufacturing branded and generic pharmaceutical products. The company has a significant presence in the women’s health and dermatology sectors, leveraging targeted sales, marketing, and education initiatives to enhance its market position.
Average Trading Volume: 395,851
Technical Sentiment Signal: Sell
Current Market Cap: A$416M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.